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The Editorial on the research topic
Cancer-Associated Defects in the DNA Damage Response: Drivers for Malignant
Transformation and Potential Therapeutic Targets
Transformation of normal cells into cancer cells almost invariably goes along with increased
levels of DNA damage. An important source of DNA damage is the enhanced activity of growth-
promoting transcription factors, such as MYC. Oncogenic activation of these transcription factors
aberrantly stimulates DNA replication, which leads to replication stress and ensuing DNA breaks.
Cells respond to this type of stress by activation of the DNA damage response (DDR). The DDR
is a complex signaling network, displaying multiple levels of cross-talk and feed-back control. Its
kinase-driven signaling axes ensure rapid responses to DNA lesions, which is complemented by its
transcriptional axis that warrants maintained signaling. Ultimately, activation of the DDR prevents
further proliferation and thus provides time to repair genotoxic lesions, and in case of excessive
levels of DNA damage promotes permanent cell cycle exit (senescence) or programmed cell death
(apoptosis). Activation of the DDR thus prevents the outgrowth of incipient tumor cells, early
during tumorigenesis.
In line with the ability to eliminate damaged cells from the proliferative compartment, the DDR
clearly has a tumor-suppressive role. Indeed, many tumor cells have inactivated parts of the DDR,
which allows proliferation in the context of DNA damage-inducing oncogenes. Not only does
partial inactivation of the DDR allow growth of transformed cells, it also provides opportunities for
therapeutic intervention. Loss of specific DDR components leaves tumor cells more dependent on
their remaining DDR components, especially under conditions of elevated levels of DNA damage
induced by chemo/radiotherapy. Identification of such synthetic vulnerabilities may lead to more
targeted therapies, in which therapeutic inactivation of the DNA damage response in cancer cells
will create more potent anti-cancer strategies.
DNA damage and the repair thereof are increasingly recognized as key pathways in normal
physiology, as well as being pathways defective in multiple pathological conditions, including
accelerated aging, neurodegeneration and cancer. In addition, the fundamental research into
the molecular underpinning of DNA repair that was initiated more than 50 years ago has now
translated into drugs that inactivate key components of the DDR with high levels of specificity.
Noteworthy, PARP inhibitors, the first molecularly targeted anti-cancer drugs that exploit the DNA
repair defect present in BRCA1- or BRCA2-mutant cancers were FDA-approved at the end of
2014. The increasing importance of this field is illustrated by the 2015 Albert Lasker Awards for
van Vugt and Reinhardt Cancer and DNA Damage Response
Biomedical Research being awarded to Stephen Elledge
and Evelyn Witkin, pioneers in uncovering the cellular
response to DNA damage. In addition, the 2015 Nobel
prize for chemistry was awarded to Thomas Lindahl, Paul
Modrich, and Aziz Sancar for their seminal work on DNA
repair.
In this “Research Topic” entitled: “Cancer-associated
defects in the DNA damage response: drivers for malignant
transformation and potential therapeutic targets,” 10 papers have
been published, focusing on various aspects of DNA damage
signaling, its effects on cellular viability and its use in cancer
therapy.
Increasingly, we realize that the DDR is complex. Rather
than being a cell-intrinsic kinase-driven linear pathway, we
understand that cell–cell communication is involved, and that it
encompasses multiple different post-translational protein marks.
Brinkmann et al., describe how ubiquitin signaling plays a
central role in the DNA damage response, whereas Jaiswal
and Lindqvist describe how extracellular signaling is used to
communicate the presence of damaged DNA to neighboring
cells. Von Morgen et al. and Lezzi and Fanciluuli, describe
the R2TP complex and Che-1/AATF, respectively, as novel
components of the cellular response to DNA damage. Ohms
et al. describe how retrotransposons are at the basis of increased
genomic instability and Shatneyeva et al. portray the interplay
between the DNA damage response and escape from immune
surveillance.
Torgovnick and Schumacher describe how defects in DNA
repair contribute to cancer initiation, and conversely, create
opportunities for targeted treatment of those cancers. As an
example of these therapeutic consequences, Knittel et al., report
how ATM loss in chronic lymphocytic leukemia creates synthetic
lethal interactions with inactivation of certain DNA repair
pathways. Additionally, Syljuasen et al., describe how therapeutic
inactivation of DNA damage checkpoint kinases could be
exploited in the treatment of lung cancer, whereas Krajewska
and van Vugt review how modulation of DNA repair through
homologous recombination can be utilized as a therapeutic
strategy.
Combined, the papers in this Research Topic underscore
the complexity of the cellular response to DNA damage, and
highlight how mechanistic insight into the (re)wiring of DDR
signaling in cancer cells can be exploited to develop novel cancer
therapeutics.
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